Sansure Biotech Inc. (SHA:688289)

Market Cap	9.14B -22.4%
Revenue (ttm)	1.61B -0.2%
Net Income	134.24M -52.3%
EPS	0.23 -52.0%
Shares Out	574.86M
PE Ratio	69.04
Forward PE	36.41
Dividend	0.52 (3.31%)
Ex-Dividend Date	Jun 22, 2026

Volume	2,487,502
Open	15.87
Previous Close	15.90
Day's Range	15.81 - 16.16
52-Week Range	13.40 - 22.94
Beta	0.49
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 27, 2026

About Sansure Biotech

Sansure Biotech Inc. researches and develops, produces, and sells in vitro diagnostic reagents and instruments in China and internationally. It offers nucleic acid and multiple nucleic acid diagnostic kits for coronavirus, CoV-2, influenza virus, and respiratory syncytial virus; DNA fluorescence and nucleic acid diagnostic kits for respiratory tract infections, HPV infections, and reproductive tract infections; nucleic acid tests and fluorescence diagnostic kits for blood-borne infections; RNA diagnostic kits for gastrointestinal infections; an...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 2008
• Employees: 2,128
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688289

Financial Performance

In 2025, Sansure Biotech's revenue was 1.64 billion, an increase of 12.58% compared to the previous year's 1.46 billion. Earnings were 198.94 million, a decrease of -27.82%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 14, 2026

Data Sources Report a data error